Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance

The Euro-GASP Network

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)


Background: The emerging resistance to the extended-spectrum cephalosporins (ESCs) in Neisseria gonorrhoeae together with increasing incidence of gonorrhoea cases in many countries have been global public health concerns. However, in recent years the levels of ESC resistance have decreased in several regions worldwide. We describe the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) data from 2013, and compare them to corresponding data from 2009-2012. Methods: During 2013, N. gonorrhoeae isolates from 21 participating countries were examined. Antimicrobial susceptibility testing (Etest or agar dilution) was performed for cefixime, ceftriaxone, ciprofloxacin, azithromycin, spectinomycin and gentamicin. Statistical analyses were performed to identify significant changes in resistance between years and to investigate associations between patients with resistant gonococcal isolates and collected epidemiological variables. Results: In total, 93 (4.7 %) of 1994 isolates displayed resistance to cefixime, representing an increase compared to the 3.9 % detected in 2012 (p = 0.23). Cefixime resistance was detected in 13 (61.9 %) of the 21 countries. Cefixime resistance among men who have sex with men was only 1.2 %, compared to 5.6 % and 6.1 % in females and male heterosexuals, respectively. The univariate analysis confirmed that isolates resistant to cefixime were more likely to be from females (OR 4.87, p < 0.01) or male heterosexuals (OR 5.32, p < 0.01). Seven (0.4 %) isolates displayed ceftriaxone resistance (in addition to cefixime resistance) compared to three and 10 isolates in 2012 and 2011, respectively. All 93 isolates with cefixime resistance were additionally resistant to ciprofloxacin and 16 (17.2 %) were also resistant to azithromycin. Among all tested isolates (n = 1994), the ciprofloxacin resistance level (52.9 %) was higher than in 2012 (50.1 %; p = 0.08), and azithromycin resistance (5.4 %) increased since 2012 (4.5 %; p = 0.16). Conclusions: In 2013, the ESC resistance was again slightly increasing in Europe. This emphasises the importance of implementing the actions outlined in the European and additional response plans, particularly activities strengthening the surveillance of antimicrobial resistance. Ceftriaxone combined with azithromycin remains a satisfactory option for the first-line treatment of gonorrhoea. However novel antimicrobials (new derivatives of previously developed antimicrobials or newly developed antimicrobials) for effective monotherapy or at least inclusion in new dual antimicrobial therapy regimens (combined with previously developed antimicrobials or novel antimicrobials) will likely be required.

Original languageEnglish
Article number321
JournalBMC Infectious Diseases
Issue number1
Publication statusPublished - 11 Aug 2015

Bibliographical note

Funding Information:
We are grateful to the whole European STI surveillance network for its contribution in the development and implementation of the Euro-GASP and the submission of gonococcal isolates and epidemiological data. The authors would like to acknowledge and thank the following ECDC staff who reviewed the manuscript: Julien Beaute, Phillip Zucs, Denis Coulombier, Andrew Amato and Mike Catchpole. And a special thank you to Cathy Ison who has contributed a great deal to the creation, implementation and co-ordination of the Euro-GASP over the years. The study was funded by the European Centre for Disease Prevention and Control (Framework Contract No. ECDC/2013/015).

Publisher Copyright:
© 2015 Cole et al.


  • Antimicrobial resistance
  • Cefixime
  • Ceftriaxone
  • Europe
  • European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP)
  • Gonorrhoea
  • Neisseria gonorrhoeae
  • Surveillance
  • Treatment


Dive into the research topics of 'Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance'. Together they form a unique fingerprint.

Cite this